Table 3:

DTI and volumetric variables of baseline and month 12 visit (mean)

	Baseline	Month 12	P Value
Patients on natalizumab (n = 22)
FA severity (z score)	−0.67 ± 0.65	−0.59 ± 0.69	.02^{^a}
MD severity (z score)	0.89 ± 0.92	0.93 ± 0.98	.81
AD severity (z score)	0.36 ± 0.40	0.43 ± 0.39	.34
RD severity (z score)	0.94 ± 1.00	0.94 ± 1.07	1.0
NGMV (L)	0.75 ± 0.04	0.75 ± 0.05	1.0
NWMV (L)	0.69 ± 0.04	0.67 ± 0.03	.008^{^a}
NBV (L)	1.44 ± 0.06	1.42 ± 0.06	.036^{^a}
T2 lesion volume (mL)^{^b}	6.2 (2.4–14.9)	6.9 (2.2–13.6)	.644
Patients on IFNb/GA (n = 17)
FA severity (z score)	−0.64 ± 0.43	−0.67 ± 0.48	.94
MD severity (z score)	0.74 ± 0.58	0.78 ± 0.58	.64
AD severity (z score)	0.26 ± 0.35	0.26 ± 0.28	1.0
RD severity (z score)	0.82 ± 0.59	0.87 ± 0.62	.43
NGMV (L)	0.73 ± 0.06	0.74 ± 0.05	1.0
NWMV (L)	0.69 ± 0.04	0.67 ± 0.03	.004^{^a}
NBV (L)	1.42 ± 0.08	1.41 ± 0.07	<.001^{^a}
T2 lesion volume (mL)^{^b}	4.9 (0.25–12.0)	5.4 (0.28–13.3)	.012^{^a}

Note:—NGMV indicates normalized gray matter volume; NWMV, normalized white matter volume.
↵a Significant difference between the time points (Bonferroni-corrected).
↵b Median and interquartile range.